Berlin, July 14, 2022 – Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer’s men’s health product Nebido™ (testosterone undecanoate), for a purchase price totaling up to 500 million Euro.Nebido for the treatment of male hypogonadism (testosterone deficiency) is available in over 80 countries since 2004…
Read More
About The Author
